SHANGHAI, Sept. 8, 2016 /PRNewswire/ -- DeltaHealth has underlined its commitment to bring a new standard of heart healthcare to the Chinese market with the opening of its first cardiovascular hospital in Shanghai.
Located in Qingpu and easily accessible to the Hongqiao transport hub, DeltaHealth's heart hospital will conveniently serve patients from the entire Yangtze River Delta region. Backed by long term investor Eight Roads, the proprietary investment arm of Fidelity International Limited, and clinical advice from Columbia HeartSource team, including clinical teams from the Divisions of Cardiology and Cardiac Surgery of Columbia University, the new DeltaHealth hospital aspires to transform the patient experience through uncompromising commitment to demonstrable patient outcomes and innovative patient service delivery.
Daniel Auerbach, Chairman of the Board of DeltaHealth said: "We want to inspire a new standard of heart care in China. As you can see by the level of detail, time and dedication spent on constructing this hospital, we are serious in our quest to bring together the best clinical care from outside and inside China."
Since 2014, DeltaHealth remained the first and only cardiovascular hospital advised by Columbia HeartSource team in China. DeltaHealth has worked closely over the past two years with the Columbia HeartSource team to develop a multidisciplinary "One Heart Team" approach to offering a seamless and integrated patient care from screening, diagnosis, treatment, through to rehabilitation, and nutrition. Craig R. Smith, MD, Johnson & Johnson Distinguished Professor and Chair of the Department of Surgery at Columbia University Medical Center said, "We are pleased that our broad experience enables us to support DeltaHealth in upgrading medical outcomes in cardiovascular care. We see our relationship with DeltaHealth as only the beginning, and will continue to work closely with the clinical teams to insure the best practices of Columbia HeartSource is successfully instilled and localized here at DeltaHealth."
DeltaHealth has an all-star clinical team headed by Professor Sun Lizhong, President & Chief Medical Officer and Professor Ge Junbo, Chief Medical Officer, Cardiology. Professor Sun is recognized as a pioneer in aortic surgeries. "Sun's Procedure" has been widely adopted across the world and is regarded as the global standard treatment for Type A aortic dissection. Professor Sun said: "DeltaHealth will become a beacon for Sino-Foreign exchange in the area of cardiovascular disease, providing a positive impetus and role model for the promotion of international standards and protocols in China." Professor Ge Junbo, also an academician at the Chinese Academy of Sciences added, "Proactive prevention and all-around patient-centric care are the fundamental tenants to building a truly innovative and transformative platform here at DeltaHealth to advance cardiovascular care."
Desmond Thio, CEO of DeltaHealth and a board member of Joint Commission International (JCI) added: "The patient lies at the heart of everything we do; from detailed pre-screening, convenient scheduling and meaningful time with physicians, to post-surgery rehabilitation and timely follow up." To insure the best patient care, DeltaHealth successfully recruited two seasoned international hospital professionals, including David Hoidal as Chief Operating Officer with over 30 years of hospital operations worldwide, and Cecilia Ma as Director of Nursing with over 30-year nursing experience in US and most recently as the Director of Patient Care of the Cardiac ICU at New York Presbyterian Hospital.
About DeltaHealth Hospital, Shanghai
DeltaHealth Hospital - Shanghai is a foreign-invested general hospital designed and constructed in accordance with Joint Commission International (JCI) and Chinese standards. It is DeltaHealth's first hospital in Shanghai. It is located in the Xujing area, 7 km to the west of Shanghai's Hongqiao transport hub. The total construction area for the project is 50,000m2, with the set-up of 202 beds during the first phase. The hospital opened in 2016. A team of top-notch physicians offer a broad range of general and specialized medical services, including complex surgical treatment of aortic aneurysm, aortic dissection, complex congenital heart disease and servere coronary heart disease.
About Eight Roads
Eight Roads (formerly Fidelity Growth Partners) is the proprietary investment arm of FIL, Fidelity International Limited, active in ventures, principal investments and real estate. Building on Fidelity's almost 50-year history of private investing, Eight Roads partners with founders, co-investors and management to build business, whether ventures or more developed companies. Eight Roads teams in Asia and Europe work alongside funds around the world, providing substantial global scale, expertise and market reach. A strong track record in China includes investments in market leaders such as, Wuxi PharmaTech, Hile, Innovent, Adagene, Hua Medicine, Optegra, Denali Therapeutics, Alibaba, iSoftstone, China PnR and Mtime.
About Columbia Heartsource
Columbia HeartSource is a management service organization established by physician leadership at Columbia University in conjunction with the Divisions of Cardiology and Cardiac Surgery. The team is comprised of senior healthcare providers, administrators, and professionals whose expertise in evaluating and implementing quality improvement programs that are second to none with demonstrated patient and quality outcome improvements. Columbia University Medical Center in New York is one of the world's leading medical institutions in cardiology and heart surgery, and it was ranked as one of the top 3 leading hospitals in Cardiology and Heart Surgery by the "U.S. News and World Report" in 2014, 2015 and again in 2016, receiving perfect scores for survival, nursing staff, advanced technologies and patient services.
